API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
RT234-PAH, based on its rapid onset of action, extended duration of action, and minimal safety and tolerability issues when used in addition to PAH maintenance therapies may allow patients to acutely relieve their episodic symptoms of PAH and improve their quality of life.
Lead Product(s): Vardenafil Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RT234-PAH
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020